3,4 diaminopyridine (3,4-DAP)
Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .
3,4 diaminopyridine (3,4-DAP). This is a voltage-dependent potassium channel blocker. Fully referenced neurology checklist.
Mechanism of action
- This is a voltage-dependent potassium channel blocker
- It increases the pre-synaptic action potential
Indications
Locked: subscribe to see this section.
Side effects
Locked: subscribe to see this section.
Indications for 4-DAP
Locked: subscribe to see this section.
Synonym
Locked: subscribe to see this section.
References
- Flet L, Polard E, Guillard O, et al. 3,4-Diaminopyridine safety in clinical practice: an observational, retrospective cohort study. J Neurol 2010; 257:937-946.
- Skeie GO, Apostolski S, Evoli A, et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 2010; 17:893-902.1
- Zhang N, Hong D, Ouyang T, et al. 3,4-diaminopyridine treatment for Lambert-Eaton myasthenic syndrome in adults: a meta-analysis of randomized controlled trials. BMC Neurol. 2021 Sep 25;21(1):371.
- Palace J, Wiles CM, Newsom-Davis J. 3,4 diaminopyridine in the treatment of congenital (hereditary) myasthenia. JNNP 1991; 54:1069-1072.
- Anlar B, Varli K, Ozdirim E, Ertan M. 3, 4-diaminopyridine in childhood myasthenia: double-blind, placebo-controlled trial. J Child Neurol 1996; 11:458–461.
- And 6 more. Subscribe to see the full list
